Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.72 USD | +1.30% | -22.42% | -40.21% |
Financials (USD)
Sales 2024 * | 968M | Sales 2025 * | 1.1B | Capitalization | 3.08B |
---|---|---|---|---|---|
Net income 2024 * | 112M | Net income 2025 * | 220M | EV / Sales 2024 * | 2.56 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 863M | EV / Sales 2025 * | 2.03 x |
P/E ratio 2024 * |
28.6
x | P/E ratio 2025 * |
14.4
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.19% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | +1.30% | ||
1 week | -20.14% | ||
Current month | -19.45% | ||
1 month | -25.45% | ||
3 months | -34.50% | ||
6 months | -24.27% | ||
Current year | -40.21% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | -.--% | - | |
1.24% | 17 M€ | -2.09% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 18.72 | +1.30% | 2,189,474 |
24-03-15 | 18.48 | -1.33% | 3,760,014 |
24-03-14 | 18.73 | -4.24% | 2,768,336 |
24-03-13 | 19.56 | -2.10% | 2,638,777 |
24-03-12 | 19.98 | -17.20% | 7,402,568 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.21% | 3.04B | |
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
-9.43% | 28.16B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B |